Allergan, Inc.  

(Public, NYSE:AGN)   Watch this stock  
Find more results for AGN
+1.38 (0.62%)
Jan 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 222.29 - 224.28
52 week 110.62 - 224.28
Open 222.37
Vol / Avg. 2.08M/2.31M
Mkt cap 66.78B
P/E 52.25
Div/yield 0.05/0.09
EPS 4.29
Shares 297.90M
Beta 0.75
Inst. own 92%
Feb 3, 2015
Q4 2014 Allergan Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2014
Actavis PLC Conference Call to Discuss its Definitive Agreement to Acquire Allergan Inc
Oct 27, 2014
Q3 2014 Allergan Inc Earnings Release
Oct 27, 2014
Q3 2014 Allergan Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 17.23% 20.20%
Operating margin 21.62% 28.72%
EBITD margin - 34.67%
Return on average assets 11.10% 12.88%
Return on average equity 18.02% 20.63%
Employees 11,500 -
CDP Score - 91 B


2525 Dupont Drive
IRVINE, CA 92612
United States - Map
+1-714-2464500 (Phone)
+1-714-2466987 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates through its two business segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products, and urologics products. The medical devices segment produces a range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Officers and directors

David E. I. Pyott Chairman of the Board, Chief Executive Officer, Principal Executive Officer
Age: 60
Bio & Compensation  - Reuters
Douglas S. Ingram Esq. President
Age: 51
Bio & Compensation  - Reuters
James M. Hindman Chief Financial Officer, Executive Vice President - Finance and Business Development
Age: 47
Bio & Compensation  - Reuters
Scott M. Whitcup M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Arnold A. Pinkston Executive Vice President, General Counsel, Assistant Secretary
Age: 55
Bio & Compensation  - Reuters
Scott D. Sherman Executive Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Raymond H. Diradoorian Executive Vice President - Global Technical Operations
Age: 56
Bio & Compensation  - Reuters
James F. Barlow Senior Vice President, Corporate Controller, Principal Accounting Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Julian S. Gangolli Corporate Vice President and President, North America
Age: 56
Bio & Compensation  - Reuters
Michael R. Gallagher Lead Independent Director
Age: 68
Bio & Compensation  - Reuters